Mountaineer-02: Phase Ii/Iii Study Of Tucatinib, Trastuzumab, Ramucirumab, And Paclitaxel In Previously Treated Her2+Gastric Or Gastroesophageal Junction Adenocarcinoma (Gec): Trial In Progress

D. V. Catenacci,J. H. Strickler,K. Shitara,Y. Nakamura,Y. Y. Janjigian,A. Barzi,T. Bekaii-Saab,H. J. Lenz,H. C. Chung,J. Tabernero,T. Yoshino,S. Siena, J. G. Mayor,M. C. Palanca-Wessels,D. Xie,J. L. Marshall

user-5f8411ab4c775e9685ff56d3（2021）

引用 14|浏览2

暂无评分

摘要

TPS252Background: Tucatinib (TUC), a highly selective HER2-directed TKI recently approved for HER2+ metastatic breast cancer (MBC), is being developed as a novel therapy for patients (pts) with met...

查看译文

关键词

Ramucirumab,Gastroesophageal Junction Adenocarcinoma,Metastatic breast cancer,Trastuzumab,Paclitaxel,Oncology,Medicine,Highly selective,Internal medicine,Previously treated

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要